Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease

Coronary Artery Disease

Volumn 7, Issue 10, 1996, Pages 723-731

  Panahloo, Arshia ^a,b   Yudkin, John S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

diabetes mellitus; fibrinolysis; insulin; PAI 1; PAI 1 gene; proinsulin like molecules

Indexed keywords

ATHEROSCLEROSIS; CORONARY RISK; DIABETES MELLITUS; DIABETIC ANGIOPATHY; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0030451085     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199610000-00005     Document Type: Review

References (82)

1. Kannel W, McGee D: Diabetes and cardiovascular disease: the Framingham study. JAMA 1979, 241:2035-2038.
2. Chmielewska J, Ranby M, Wiman B: Evidence for a rapid inhibitor to tPA in plasma. Thromb Res 1983, 31:427-463.
3. Declerck PJ, Verstreken M, Collen D: Measurement of different forms of plasminogen activator inhibitor-1 (PAI-1) using various monoclonal antibody based enzyme-linked immunosorbent assays. Fibrinolysis 1990, 4 (suppl 2):132-133.
4. Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D: Measurement of plasminogen activator inhibitor-1 in biological fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988, 1:220-225.
5. Auwerx J, Bouillon R, Collen D, Geboers J: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988, 8:68-72.
6. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I: Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994, 72:44-53. In atherosclerotic vessels, PAI-1 expression was observed in neovessels surrounding the lesion, in intimal cells and in smooth muscle cells. This local increase in PAI-1 could lead to fibrin deposition during plaque rupture, contributing to the development and progression of the lesion.
7. Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J: Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995, 15:893-902. Quantitative analyses of activity and antigen levels of individual components of the fibrinolytic system was analysed in serial sections of aortic tissue obtained during autopsy. An excess of PAI-1 over plasminogen activators was found in atherosclerotic lesions of the human aorta.
8. Miskin R, Axelrod JH, Griep AE, Lee E, Belin D, Vassalli JD, et al.: Human and murine urokinase cDNAs linked to the murine A-crystallin promoter exhibit lens and non-lens expression in transgenic mice. Eur J Biochem 1990, 190:31-38.
9. Gris JC, Schved JF, Feugeas O, Aguilar-Martinez P, Arund A, Sanchez N, et al.: Impact of smoking, physical training and weight reduction on FVII and haemostatic markers in sedentary men. Thromb Haemostas 1990, 64:516-520.
10. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, et al.: Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Atheroscler Thromb 1993, 13:162-169.
11. Gough SCL, McCormack L, Rice PJS, Grant PJ: The fibrinolytic response to exercise at diagnosis and after 12 months in patients with type 2 diabetes mellitus. Fibrinolysis 1994, 8:372-377.
12. Grant PJ, Kruithof EKO, Felly CP, Felber JP, Bachmann F: Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 1990, 79:513-516.
13. Vuorinen-Markkola H, Puhakainen I, Yki-Järvinen H: No evidence of short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemost 1992, 67:117-120.
14. McCormack L, Strickland MH, Grant PJ: Plasminogen activator inhibitor-1 antigen concentrations during insulin and oral glucose tolerance tests in obese man. Fibrinolysis 1993, 7:225-228.
15. Barriocanal LA, Mishra V, Tarbit M, Kesteven P, Alberti KGMM, Walker M: The effect of triglyceride infusion on the regulators of fibrinolysis. Fibrinolysis 1995, 9:243-246.
16. Grant PJ, Stickland MH, Booth NA, Prentice CRM: Metformin causes a reduction in post venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabetic Med 1991, 8:361-365.
17. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993, 16:4621-4629.
18. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS: Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabetic Med 1993, 10:27-32.
19. Panahloo A, Mohamed-Ali V, Denver E, Yudkin JS: The effect of hypoglycaemic therapy in subjects with non-insulin-dependent diabetes on insulin sensitivity, fibrinolysis and lipids [abstract]. Diabetic Med 1995, 12:P76.
20. Nordt T, Sawa H, Fujii S, Sobel E: Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995, 91:764-770. The first in-vivo study, showing that infusions of proinsulin as well as insulin increase plasma PAI-1 activity in rabbits. PAI-1 messenger RNA was increased in aorta and liver. The results suggest that elevated levels of both proinsulin and insulin in NIDDM may increase plasma PAI-1 activity.
21. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D: Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb Haemost 1988, 60:491-494.
22. Kooistra T, Bosma PJ, Töns HAM, van den Berg AP, Meyer P, Princen HMG: Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989, 62:723-728.
23. Grant PJ, Rüegg M, Medcalf RL: Basal expression and insulin-mediated induction of PAI-1 mRNA in HepG2 cells. Fibrinolysis 1991, 5:81-86.
24. Schneider DJ, Sobel BE: Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implication for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA 1991, 88:9959-9963.
25. Schneider DJ, Nordt TK, Sobel BE: Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 1992, 41:890-895.
26. Anfosso F, Chomiki N, Alessi MC, Vague P, Juhan-Vague I: Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2: metformin inhibits the stimulating effect of insulin. J Clin Invest 1993, 91:2185-2193. An insulin-resistant state was induced in HepG2 cells by preincubation with insulin. Increased PAI-1 synthesis was demonstrated in these 'resistant' cells, an effect that was blocked by the drug metformin.
27. Klassen KJ, Nordt TK, Schneider DJ, Sobel BE: Constitutive biosynthesis of plasminogen activator inhibitor type-1 (PAI-1) by cultured human aortic endothelial cells independent of insulin. Coronary Artery Dis 1993, 4:713-719.
28. Nordt T, Schneider D, Sobel E: Augmentation of synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994, 89:321-330.
29. Alessi MC, Anfosso F, Henry M, Peiretti F, Nalbone G, Juhan-Vague I: Upregulation of PAI-1 synthesis by insulin and proinsulin in HepG2 cells but not in endothelial cells. Fibrinolysis 1995, 9:237-242.
30. Pyörälä K, Savolainen S, Kaukola S, Haapakoski J: Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 year follow-up of the Helsinki policeman study population. Acta Med Scand 1985, 701 (suppl):38-52.
31. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P: Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients: relationship with plasma insulin. Thromb Haemost 1989, 61:370-373.
32. Juhan-Vague I, Thompson SG, Jespersen J: Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Atheroscler Thromb 1993, 13:1865-1873. A strong relationship was observed between plasma insulin and PAI-1 in 1484 patients in the ECAT angina pectoris study.
33. Yudkin JS: Circulating proinsulinlike molecules. J Diab Comp 1993, 7:113-123.
34. Nagi NK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, et al.: The relationship of concentrations of insulin, intact proinsulin and 32,33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990, 33:532-537.
35. Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, et al.: Biosynthetic human proinsulin: review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992, 15:666-692.
36. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries S, Yudkin JS: Determinants of PAI-1 activity in treated type 2 diabetes and its relation to a polymorphism in the PAI-1 gene. Diabetes 1995, 44:37-42. A cross-sectional study in 146 patients with NIDDM, relating PAI-1 activity to cardiovascular risk factors, the 4G/5G promoter poymorphism of the PAI-1 gene and hypoglycaemic therapy. The PAI-1 genotype-triglyceride interaction and insulin sensitivity were the major determinants of PAI-1 activity.
37. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE: The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993, 42:945-949.
38. Maiello M, Boeri D, Podesta F, Cagliero E, Vichi M, Odetti P, et al.: Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 1992, 41:1009-1015.
39. Nordt TK, Klassen JK, Schneider DJ, Sobel BE: Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implication for local fibrinolysis. Arterioscler Thromb 1993, 13:1822-1828.
40. Auwerx J, Bouillon R, Collen D, Geboers J: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988, 8:68-72.
41. Mansfield MW, Stickland MH, Carter AM, Grant PJ: Polymorphism of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 1994, 71:731-736.
42. West KM, Ahuja MMS, Bennett PH, Czyczk A, de Acosta OM, Fuller JH, et al.: The role of circulating glucose and triglyceride concentrations and their interactions with other 'risk factors' as determinants of arterial disease in nine diabetic population samples from the WHO Multinational Study. Diabetes Care 1983, 6:361-369.
43. Fontbonne AM, Eschwege EM, Cambien F, Richard JL, Ducimetière P, Thibult N, et al.: Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11 year follow-up of the Paris Prospective study. Diabetologia 1989, 32:300-304.
44. Laakso M, Lehto S, Penttilä, Pyörälä K: Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993, 88:1421-1430.
45. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Allessi MC, et al.: Correlations between blood fibrinolytic activity, plasminogen activator inhibitor levels, plasma insulin and relative body weight in normal and obese subjects. Metabolism 1986, 35:250-253.
46. Mehta J, Mehta P, Lawson D, Goldeen T: Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987, 9:263-268.
47. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA: Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993, 36:817-825. VLDL triglyceride concentrations in normo- and hypertriglyceridaemic men were the major determinant of plasma PAI-1 activity.
48. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, et al.: Hypertriglyceridemia and regulation of fibrinolytic activity. Artenoscler Thromb 1992, 12:19-27.
49. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J: Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein cells is induced by very low density lipoprotein. Arteriosclerosis 1990, 10:1067-1073.
50. Tremoli E, Camera M, Maderna P, Sironi L, Prati L, Colli S, et al.: Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. Arterioscler Thromb 1993, 13:338-346.
51. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I: Stimulating effect of oxidised low density lipoprotein on plasminogen activator inhibitor-1 synthesis by endothelial cells. Atherosder Thromb 1991, 6:1821-1829.
52. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, et al.: Transferable lipids in oxidised low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 1993, 73:335-343.
53. Etingin O, Hajjar D, Hajjar K, Harpel P, Nachman R: Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991, 266:2459-2465.
54. Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK, et al.: Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 1994, 14:438-442.
55. Zysow BR, Lawn RM: The relationship of lipoprotein(a) to haemostasis. Curr Opin Lipidol 1993, 4:484-489.
56. Palabricia TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC: Antifibrinolytic activity of apolipoprotein(a): transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Med 1995, 1:256-259. A direct effect in vivo of apolipoprotein(a) on fibrinolysis was demonstrated in transgenic mice expressing the apolipoprotein (a) gene.
57. Bastard JP, Bruckert E, Robert JJ, Ankri A, Grimaldi A, Jardel C, et al.: Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity? Int J Obesity 1995, 19:836-838.
58. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991, 11:183-190.
59. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney A: The two allele sequence of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene responds differently to IL-1 in HEPG2 cells. J Biol Chem 1993, 268:10739-10745. A common single-base-pair insertion(5G)/deletion (4G) polymorphism was detected in the promoter region of the PAI-1 gene. In young survivors of myocardial infarction, individuals possessing the 4G allele had higher plasma PAI-1 activity.
60. Eriksson P, Kallin B, van T Hooft FM, Båvenholm P, Hamsten A: Allele specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995, 92:1851-1855. The prevalence of the 4G-allele of the 4G/5G promoter polymorphism of the PAI-1 gene was significantly higher in young patients with myocardial infarction. The 4G-allele-specific increase in plasma PAI-1 activity was related to differential binding of transcription factors.
61. Mansfield MW, Stickland MH, Grant PJ: Plasminogen activator inhibitor (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995, 74:1032-1034.
62. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al.: The 4G/4G genetic polymorphism in the promoter of the ploasminogen activator inhibitor-1 gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995, 74:837-841.
63. Mansfield MW, Stickland MH, Grant PJ: Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995, 74:842-847.
64. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ: Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park heart study. Lancet 1993, 342:1076-1079. Low fibrinolytic activity, as measured by the dilute clot lysis time, appeared to be a strong determinant of CAD.
65. Hamsten A, Wiman B, De Faire U, Blombäck M: Increased plasma level of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985, 40:113-121.
66. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al.: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, ii:3-9.
67. Yudkin JS, Hendra TJ: Vascular events and diabetes: acute myocardial infarction and stroke. International Textbook of Diabetes Mellitus. London: John Wiley & Sons Ltd, 1992.
68. Gray RP, Yudkin JS, Patterson DL: Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br Heart J 1993, 69:228-232.
69. Gray RP, Yudkin JS, Patterson DL: Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 1993, 70:530-536.
70. Jokl R, Laimins M, Klein RL, Lyons TJ, Lopes-Virella MF, Colwell JA: Platelet plasminogen activator inhibitor-1 in patients with type II diabetes. Diabetes Care 1994, 17:818-823.
71. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993, 341:1165-1168. Elevated t-PA antigen was associated with increased risk of future myocardial infarction.
72. Jansson JH, Olofsson BO, Nilsson TK: Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease a 7-year follow-up. Circulation 1993, 88:2030-2034. Concentrations of t-PA antigen were related to the long-term risk of death in patients with angina and angiographically proven CAD. This paradoxical effect and increase in t-PA antigen probably reflects t-PA-PAI-1 complex formation.
73. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de Loo JCW, for the European Concentrated Action on Thrombosis and Disabilities Angina Pectoris Study Group: Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995, 332:635-641. Plasma concentrations of fibrinogen, von Willebrand factor antigen, and t-PA antigen were independent predictors of subsequent myocardial infarction or sudden death from coronary artery disease among 3000 subjects in the ECAT Angina Pectoris study.
74. Garcia Frade LJ, de la Calle H, Torrado MC, Lara JI, Cuellar L, Garcia Avello A: Hypofibrinolysis associated with vasculopathy in noninsulin dependent diabetes mellitus. Thromb Res 1990, 59:51-59.
75. Haitas B, Barnes AJ, Cederholm-Williams SA, Moore J, Shgry MEC, Turner RC: Abnormal endothelial release of fibrinolytic activity and fibronectin in diabetic microangiopathy. Diabetologia 1984, 27:493-496.
76. Walmsley D, Hampton KK, Grant PJ: Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin dependent) diabetes. Diab Med 1991, 8:954-959.
77. Maser RE, Ellis D, Erbey JR, Orchard TJ: Little relationship of plasminogen activator inhibitor (PAI-1) with complications of insulin-dependent diabetes diabetes mellitus: Pittsburg Epidemiology of Diabetes Complications study. Fibrinolysis 1995, 9:139-144.
78. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970, 19 (suppl 2):747-830.
79. Fujii S, Sobel BE: Direct effects of gemfibrozil on the fibrinolytic system: diminution of plasminogen activator inhibitor type 1. Circulation 1992, 85:1888-1893. Pharmacological concentrations of gemfibrozil directly affected PAI-1 synthesis by decreasing basal PAI-1 secretion in HepG2 cells and also that induced by epidermal growth factor and transforming growth factor-β.
80. Brown SL, Sobel BE, Fujii S: Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin: a potential link between lipid lowering and fibrinolysis. Circulation 1995, 92:767-772. Niacin not only decreases the constitutive synthesis of PAI-1 by HepG2 cells but also attenuates the induction of PAI-1 synthesis by transforming growth factor-β. Niacin may potentiate fibrinolysis, reducing the induction of atherothrombosis by clot-associated mitogens.
81. Lundgren CH, Brown SL, Nordt TK, Sobel BD, Fujii S: Elaboration of type-1 plasminogen activator inhibitor from adipocytes. Circulation 1996, 93:106-110. Expression of PAI-1 was demonstrated in adipose tissue suggesting a novel mechanism by which obesity leads to increased plasma PAI-1 and, consequently, accelerated atherosclerosis.
82. Samad S, Yamamoto K, Luskutoff DJ: Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. J Clin Invest 1996, 97:37-46.